In the last trading session, 0.63 million shares of the C4 Therapeutics Inc (NASDAQ:CCCC) were traded, and its beta was 2.95. Most recently the company’s share price was $3.37, and it changed around -$0.18 or -5.07% from the last close, which brings the market valuation of the company to $237.88M. CCCC currently trades at a discount to its 52-week high of $11.88, offering almost -252.52% off that amount. The share price’s 52-week low was $3.25, which indicates that the current value has risen by an impressive 3.56% since then. We note from C4 Therapeutics Inc’s average daily trading volume that its 10-day average is 1.81 million shares, with the 3-month average coming to 1.75 million.
C4 Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.67. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended CCCC as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. C4 Therapeutics Inc is expected to report earnings per share of -0.44 for the current quarter.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Instantly CCCC has showed a red trend with a performance of -5.07% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.72 on recent trading dayincreased the stock’s daily price by 9.41%. The company’s shares are currently down -6.39% year-to-date, but still up 0.30% over the last five days. On the other hand, C4 Therapeutics Inc (NASDAQ:CCCC) is -12.24% down in the 30-day period. We can see from the shorts that 9.28 million shares have been sold at a short interest cover period of 4.72 day(s).
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 78.94% from its current value. Analyst projections state that CCCC is forecast to be at a low of $12 and a high of $20.
C4 Therapeutics Inc (CCCC) estimates and forecasts
The year-over-year growth rate is expected to be 72.57%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 4.33M in revenue for the current quarter. 3 analysts expect C4 Therapeutics Inc to make 3.33M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.26M and 3.04M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 32.88%. Forecasts for the next quarter put sales growth at 9.69%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -36.05%. C4 Therapeutics Inc earnings are expected to increase by 42.65% in 2025, but the outlook is positive 12.00% per year for the next five years.
CCCC Dividends
C4 Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.42% of C4 Therapeutics Inc shares, and 92.50% of them are in the hands of institutional investors. The stock currently has a share float of 104.43%. C4 Therapeutics Inc stock is held by 158.0 institutions, with LYNX1 CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 9.9993% of the shares, which is about 6.88 million shares worth $31.79 million.
RA CAPITAL MANAGEMENT, L.P., with 7.0891% or 4.88 million shares worth $22.54 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.61 shares worth $8.8 million, making up 3.70% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.14 shares worth around $7.2 million, which represents about 3.03% of the total shares outstanding.
